Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. OMERACT Definitions for Ultrasonographic Pathologies and Elementary Lesions of Rheumatic Disorders 15 Years On

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. OMERACT Development of a Core Domain Set of Outcomes for Shared Decision-making Interventions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Type 2 diabetes remission one year after an intensive lifestyle intervention: A secondary analysis of a randomized clinical trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Kathleen M Andersen
  • Ayano Kelly
  • Anne Lyddiatt
  • Clifton O Bingham
  • Vivian P Bykerk
  • Adena Batterman
  • Joan Westreich
  • Michelle K Jones
  • Marita Cross
  • Peter M Brooks
  • Lyn March
  • Beverley Shea
  • Peter Tugwell
  • Lee S Simon
  • Robin Christensen
  • Susan J Bartlett
Vis graf over relationer

OBJECTIVE: The Outcome Measures in Rheumatology (OMERACT) Safety Working Group is identifying core safety domains that matter most to patients with rheumatic disease.

METHODS: International focus groups were held with 39 patients with inflammatory arthritis to identify disease-modifying antirheumatic drug (DMARD) experiences and concerns. Themes were identified by pragmatic thematic coding and discussed in small groups by meeting attendees.

RESULTS: Patients view DMARD side effects as a continuum and consider the cumulative effect on day-to-day function. Disease and drug experiences, personal factors, and life circumstances influence tolerance of side effects and treatment persistence.

CONCLUSION: Patients weigh overall adverse effects and benefits over time in relation to experiences and life circumstances.

OriginalsprogEngelsk
TidsskriftJournal of Rheumatology
Vol/bind46
Udgave nummer9
Sider (fra-til)1168-1172
Antal sider5
ISSN0315-162X
DOI
StatusUdgivet - sep. 2019

ID: 58098031